Ampio (AMPE) Expands AIK Enrollment in Australia
Tweet
Share
E-mailGet Alerts AMPE Hot Sheet
Join SI Premium – FREE
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia. Forty-two (42) patients were added to the original sixty (60) patient study.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Provident Financial prices $175M subordinated notes at 6.50%
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
